An 83-year-old patient developed erosions and a blister of the gingival mucous membrane,
6 months after discontinuation of the anti-programmed death-1 (anti PD-1) pembrolizumab …

Cancer immunotherapy has fundamentally altered cancer treatment; however, its efficacy is
limited to a subset of patients in most clinical settings. The immune system plays a key role …

Uveal melanoma is considered a rare disease but it is the most common intraocular
malignancy in adults. Local treatments are effective, but the systemic recurrence rate is …

Melanoma has been the most important cancer to drive immunotherapy development of
solid tumors. Since 2010, immunotherapy has been revolutionized by the concept of …

Immunotherapy with anti–programmed cell death-1 (PD-1) agents is an effective treatment
for metastatic melanoma. Recent data hint at better response to therapy for patients over age …

To understand prognostic factors for outcome between differentially sequenced nivolumab
and ipilimumab in a randomized phase II trial, we measured T-cell infiltration and PD-L1 by …

Radiation-induced immune effects have been extensively deciphered over the last few
years, leading to the concept of the dual immune effect of radiotherapy with both …

Abstract Purpose Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have
improved the survival of people with metastatic melanoma. We assessed the feasibility …

Abstract Background Metastatic Merkel cell carcinoma (mMCC) is highly responsive to
immune checkpoint inhibitors (ICIs); however, durability of response after treatment …

The efficacy of anti-programmed death-1 (PD-1) monotherapy for advanced melanoma has
been established, but it is unknown to what extent patients benefit in the real world. In this …